Rarecyte
Rarecyte is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC
Sponsor Triana Biomedicines Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor Celcuity Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants with Locally Advanced or Metastatic Solid Tumors
Sponsor Astellas Pharma Global Development Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Rarecyte?
The 2026-10-09 snapshot links Rarecyte to 3 distinct CTIS trials. Recorded services include Laboratory services, Analysis of tissue samples. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Rarecyte?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Rarecyte conducted?
The linked trials record locations in 4 countries, including Spain, France, Germany, Italy. These are trial locations, not confirmed office locations or countries where Rarecyte delivered services.
What can this page tell me about Rarecyte's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Rarecyte. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Rarecyte Inc.